JCRB1916 TCC-NECT-2
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1916 | Cell Name | TCC-NECT-2 |
|---|---|---|---|
| Profile | Duodenal neuroendocrine tumor. Derived from metastatic site: Ascites. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 59-year-old |
| Identity | available | Tissue for Primary Cancer | duodenum |
| Case history | Duodenal neuroendocrine tumor. Derived from metastatic site: Ascites. | Metastasis | Y |
| Tissue Metastasized | ascites | Genetics | BRAF p.Val600Glu (c.1799T>A), Homozygous for TP53 c.783-1G>A; splice acceptor mutation |
| Life Span | infinite | Crisis PDL | |
| Morphology | round shape | Character | Doubling time: ~31.4 hours, Floating cells. |
| Classify | tumor | Established by | Yanagihara Kazuyoshi |
| Registered by | Yuki Iino | Regulation for Distribution | |
| Comment | Year | ||
| Medium | RPMI1640 medium + 10% FBS | Methods for Passages | dilution |
| Cell Number on Passage | split ratio=1/10 | Race | Japanese |
| CO2 Conc. | 5% | Tissue Sampling | duodenum |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:30559933 | Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma. Yanagihara K,Kubo T,Mihara K,Kuwata T,Ochiai A,Seyama T,Yokozaki H Oncotarget. 2018 Nov 23;9(92):36503-36514 |
| Pubmed id:29765522 | Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. Ohmoto A,Suzuki M,Takai E,Rokutan H,Fujiwara Y,Morizane C,Yanagihara K,Shibata T,Yachida S Oncotarget. 2018 Apr 20;9(30):21086-21099 |
| Images |
|---|
      |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB1916 | Cell Name | TCC-NECT-2 |
|---|---|---|---|
| LOT No. | 09092022 | Lot Specification | distribution |
| Medium | RPMI1640 medium (GIBCO:Cat No.11875) with 10% heat inactivated fetal bovine serum (SIGMA, Cat#172012, Lot#12J396) | Temperature | 37 C |
| Cell Density at Seeding | 0.5-2.01x10^5 cells/ml | Methods for Passages | dilution |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.26x10^6 |
| Viability at cell freezing (%) | 97 | Antibiotics Used | free |
| Passage Number | p4* | PDL | NT |
| Sterility: MYCOPLASMA | Sterility: BACTERIA | ||
| Sterility: FUNGI | Isozyme Analysis | ||
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:11 D13S317:9,11 D7S820:10 D16S539:10,13 VWA:18,20 TH01:9 AM:X TPOX:8 CSF1PO:13 |
| Adhesion | Exoteric Gene | NT | |
| Medium for Freezing | BAMBANKER (LYMPHOTEC Inc., CS-02-001, NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 96 | Additional information |
| Images |
|---|
|
|